Advanced Search Results For "POLY(ADP-ribose) polymerase"
Your filters
Triumphs and challenges in exploiting poly(ADP-ribose) polymerase inhibition to combat triple-negative breast cancer.
Publication Type: Academic Journal
Source(s): Journal of cellular physiology [J Cell Physiol] 2023 Aug; Vol. 238 (8), pp. 1625-1640. Date of Electronic Publication: 2023 Apr 12.
Abstract: Poly(ADP-ribose) polymerase 1 (PARP1) regulates a myriad of DNA repair mechanisms to preserve genomic integrity following DNA damage. PARP inhibitors (PARPi) confer synthetic lethality in malignancies with a deficiency in the homologous recombination (...
The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer.
Publication Type: Academic Journal
Source(s): European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2023 Oct; Vol. 192, pp. 113249. Date of Electronic Publication: 2023 Jul 23.
Abstract: For about a decade, poly [ADP ribose] polymerases (PARP) inhibitors have been used almost exclusively to treat tumours that are deficient in one of the BRCA genes. In advanced prostate cancer, which is largely driven by the activity of the androgen rec...
Discovery, Synthesis, and Evaluation of Novel Dual Inhibitors of a Vascular Endothelial Growth Factor Receptor and Poly(ADP-Ribose) Polymerase for BRCA Wild-Type Breast Cancer Therapy.
Publication Type: Academic Journal
Source(s): Journal of medicinal chemistry [J Med Chem] 2023 Sep 14; Vol. 66 (17), pp. 12069-12100. Date of Electronic Publication: 2023 Aug 24.
Abstract: Poly(ADP-ribose) polymerase (PARP) inhibitors have been approved for the treatment of breast cancer (BC) with breast cancer susceptibility (BRCA) gene mutation. Leveraging new synthetic lethal interactions may be an effective way to broaden the indicat...
An attempt to establish real-world databases of poly(ADP-ribose) polymerase inhibitors for advanced or recurrent epithelial ovarian cancer: the Japanese Gynecologic Oncology Group.
Publication Type: Academic Journal
Source(s): Journal of gynecologic oncology [J Gynecol Oncol] 2023 May; Vol. 34 (3), pp. e62. Date of Electronic Publication: 2023 Apr 21.
Abstract: The development of new treatments for gynecological malignancies has been conducted mainly through collaborative international phase III trials led by the United States and Europe. The survival outcomes of many gynecological malignancies have greatly i...
Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours.
Publication Type: Report
Source(s): British journal of haematology [Br J Haematol] 2023 May; Vol. 201 (3), pp. e25-e29. Date of Electronic Publication: 2023 Mar 23.
PARP-nucleic acid interactions: Allosteric signaling, PARP inhibitor types, DNA bridges, and viral RNA surveillance.
Publication Type: Academic Journal
Source(s): Current opinion in structural biology [Curr Opin Struct Biol] 2023 Aug; Vol. 81, pp. 102643. Date of Electronic Publication: 2023 Jun 21.
Abstract: PARP enzymes create ADP-ribose modifications to regulate multiple facets of human biology, and some prominent PARP family members are best known for the nucleic acid interactions that regulate their activities and functions. Recent structural studies h...
Poly(ADP-Ribose) Polymerase-1 Lacking Enzymatic Activity Is Not Compatible with Mouse Development.
Publication Type: Academic Journal
Source(s): Cells [Cells] 2023 Aug 16; Vol. 12 (16). Date of Electronic Publication: 2023 Aug 16.
Abstract: Poly(ADP-ribose) polymerase-1 (PARP1) binds DNA lesions to catalyse poly(ADP-ribosyl)ation (PARylation) using NAD+ as a substrate. PARP1 plays multiple roles in cellular activities, including DNA repair, transcription, cell death, and chromatin remodel...
A New Opportunity for "Old" Molecules: Targeting PARP1 Activity through a Non-Enzymatic Mechanism.
Publication Type: Academic Journal
Source(s): International journal of molecular sciences [Int J Mol Sci] 2023 May 16; Vol. 24 (10). Date of Electronic Publication: 2023 May 16.
Abstract: In recent years, new therapies have been developed based on molecules that target molecular mechanisms involved in both the initiation and maintenance of the oncogenic process. Among these molecules are the poly(ADP-ribose) polymerase 1 (PARP1) inhibit...
Cost-effectiveness of poly-(ADP-ribose) polymerase (PARP)-inhibitors for the maintenance treatment after responding to first- and second-line chemotherapy in advanced ovarian cancer.
Publication Type: Academic Journal
Source(s): Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2023 Mar; Vol. 29 (2), pp. 457-464. Date of Electronic Publication: 2022 Nov 07.
Abstract: The introduction of inhibitors of poly-(ADP-ribose) polymerase (PARP) for the treatment of women with epithelial ovarian cancers (EOC) has radically changed the treatment in maintenance setting after responding to first- and second-line chemotherapy. T...